Harpoon Therapeutics, Inc. stock is up 2.68% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 March’s closed higher than February. 0% of analysts rate it a buy.
Harpoon Therapeutics, Inc. engages in the development of a novel class of T cell engagers that harness the power of the body's immune system. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!